Pharmacy Times
AUGUST 11, 2022
Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.
Pharmaceutical Commerce
AUGUST 11, 2022
Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
AUGUST 11, 2022
A recent study suggests that homologous and heterologous vaccines protect against the Omicron variant of COVID-19, but the heterologous appears more durable.
European Pharmaceutical Review
AUGUST 11, 2022
The Frost & Sullivan Institute stated that it is proud to present Samsung Biologics with the 2022 Enlightened Growth Leadership Award for not only demonstrating growth excellence but also social responsibility. In announcing the award, the Institute asserted that it “believes that all organisations must either create or become part of a solution that addresses threats to humanity,” highlighting Samsung’s strong environmental, social and governance (ESG) and sustainability initiatives the rea
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
AUGUST 11, 2022
Organizational culture is determined by how the organizational leadership responds to a crisis, how they adapt to new demands and how they correct an employee when mistakes happen.
pharmaphorum
AUGUST 11, 2022
GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer. That’s the conclusion of analysts at Morgan Stanley, Deutsche Bank and UBS, who have all issued research notes drawing attention to the issue, which has remained largely off the radar since sales of Zantac (ranitidine) were halted.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmaceutical Commerce
AUGUST 11, 2022
Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID.
Pharmacy Times
AUGUST 11, 2022
Lebrikizumab is a novel monoclonal antibody that binds with high affinity to the IL-13 protein to prevent the interaction between IL-13R?1 and IL-4R?, which blocks downstream signal activation along the IL-13 pathway.
pharmaphorum
AUGUST 11, 2022
More than 60 percent of all American adults take prescription drugs , amounting to approximately 131 million individuals. These drugs have been rigorously tested by regulatory bodies around the world before they’re made available to ensure they work as labelled, but despite that, adverse events crop up. In 2016, the estimated annual cost of drug-related morbidity and mortality resulting from non-optimised medication therapy was $528.4 billion in the United States alone.
PharmaVoice
AUGUST 11, 2022
What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
European Pharmaceutical Review
AUGUST 11, 2022
Hospitalised patients on high-flow oxygen for severe COVID-19 pneumonia were nearly 50 percent less likely to die when treated with antiviral remdesivir in combination with steroid dexamethasone and baricitinib, according to research from Rutgers Ernest Mario School of Pharmacy in the US. The research was published in the Canadian Journal of Infectious Diseases and Medical Microbiology in July. .
Pharmacy Times
AUGUST 11, 2022
Ten category winners will be recognized for their achievements in the pharmacy profession at the Next-Generation Pharmacist® of the Year gala held on September 30, 2022, in Kansas City, Mo.
Pharmaceutical Technology
AUGUST 11, 2022
Asthma is a chronic respiratory condition that, according to GlobalData’s Epidemiology Database, affects approximately 14% of the UK population, and almost 88 million people in the seven major markets worldwide (US, UK, France, Germany, Italy, Spain, and Japan). Common symptoms include wheezing, shortness of breath, and limited airflow, which can vary in severity.
Pharmacy Times
AUGUST 11, 2022
There are several key areas of risk that infusion practices are likely to face at some point, and proactively preparing for these events can help ensure a positive outcome.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
AUGUST 11, 2022
Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products Regulatory Agency (MHRA). Pluvicto (lutetium (177Lu) vipivotide tetraxetan) has been cleared for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with androgen receptor inhibitors and taxane-based chemotherapy or not medically suitable for taxane drugs.
Pharmacy Times
AUGUST 11, 2022
The interim analysis of the TROPION-Lung02 trial demonstrate an overall response rate of 37% in individuals who were treated with datopotamab deruxtecan and pembrolizumab.
pharmaphorum
AUGUST 11, 2022
The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting. Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling , defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines , exploring novel drug designs
Pharmacy Times
AUGUST 11, 2022
Moxifloxacin hydrochloride (Avelox) is indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria.
Pharmaceutical Technology
AUGUST 11, 2022
Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. To back the merger, Disc raised funds worth $53.5m from a group of healthcare investors led by Access Biotechnology and also include OrbiMed, Atlas Venture and 5AM Ventures among others. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.
Outsourcing Pharma
AUGUST 11, 2022
A leader from the behavioral science specialist shares ways to use precision engagement and other methods to increase patient adherence in clinical studies.
InCrowd
AUGUST 11, 2022
With the growing popularity of at-home testing for genetics, we asked Genetic Counselors their thoughts on at-home testing and its efficacy. We first asked – What do you think about patients doing at home testing? For example, Everlywell, LetsGetChecked, 23andMe etc? On a scale of 1 to 7, with 7 being strongly agree, most questions averaged in the middle ground of 3.17-5.75 with the strongest opinions being on accuracy of the tests and the importance of consulting with a healthcare provide
Pharmacy Friday Pearls
AUGUST 11, 2022
Download PDF. Introduction. Rapid sequence intubation (RSI) is a process whereby an induction agent and a neuromuscular blocking agent are given in rapid succession to facilitate endotracheal intubation The immediate post intubation period in the ED is a critical time for continued patient stabilization. While physical adjuncts like securing the tube, in line suctioning, and elevating the head of the bed are part of general post intubation management, post intubation analgesia and sedation is a
Pharmaceutical Technology
AUGUST 11, 2022
Spain’s pharma industry registered an 18.3% rise in IT hiring activity in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring increased by 1.22% in July 2022 when compared with June 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 9.33% share in July 2022, recording a decrease of 0.91% over the last three-month average share.
pharmaphorum
AUGUST 11, 2022
Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple myeloma, after reporting that it met its objectives in a phase 3 trial. 2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third-line treatment with the CAR-T.
Pharmaceutical Technology
AUGUST 11, 2022
The US’s pharma industry registered a 5.1% drop in IT hiring activity in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The industry’s overall hiring is decreased by 4.42% in July 2022 when compared with June 2022. Out of the pharma industry’s total hiring activity, IT jobs claimed a 1.92% share in July 2022, recording an increase of 0.06% over the last three-month average share.
pharmaphorum
AUGUST 11, 2022
One of the digital health sector’s latest unicorn companies – Biofourmis – has upscaled its recent fourth round financing, adding $20 million to the $300 million it raised in April. The top-up comes from Intel Capital, the strategic investment arm of chipmaker Intel, and has been announced alongside two new additions to Biofourmis’ board of directors.
Pharmaceutical Technology
AUGUST 11, 2022
UK-based company AstraZeneca’s IT hiring rose 8.9% in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity increased by 8.89% in July 2022 when compared with June 2022. IT jobs claimed an 8.1% share in the company’s total hiring activity in July 2022, and recorded a 0.25% decline over the last three-month average share.
pharmaphorum
AUGUST 11, 2022
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz. Rebecca speaks about generics and biosimilars: what they are, why they’re important for medication access and healthcare cost sustainability, and what Sandoz has learned about succeeding in the off-patent world.
Pharmaceutical Technology
AUGUST 11, 2022
Germany-based company Bayer’s IT hiring declined 6.6% in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity declined by 5.98% in July 2022 when compared with June 2022. IT jobs claimed a 6.13% share in the company’s total hiring activity in July 2022, and recorded a 0.12% growth over the last three-month average share.
pharmaphorum
AUGUST 11, 2022
The innovative Global Malnutrition Composite Score, approved by Centers for Medicare & Medicaid Services (CMS), will empower providers to deliver higher-quality care to patients. Hospital facilities will be able to improve the quality of care for patients with malnutrition and reduce hospital stays and costs by leveraging a new measure developed by our policy specialist consultants at Avalere Health and the Academy of Nutrition and Dietetics.
Pharmaceutical Technology
AUGUST 11, 2022
Luxembourg-based company Eurofins Scientific’s IT hiring declined 1.4% in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity increased by 0.58% in July 2022 when compared with June 2022. IT jobs claimed a 5.85% share in the company’s total hiring activity in July 2022, and recorded a 0.51% decline over the last three-month average share.
pharmaphorum
AUGUST 11, 2022
Figures from the UK Office for National Statistics (ONS) have revealed that the number of people with higher levels of COVID-19 antibodies in their blood is declining quickly – leading to calls for booster vaccination campaigns to be started as soon as possible. The ONS survey – based on swab and blood samples from thousands of households across the country – found that the proportion of people in England with antibody levels of at least 800 ng/ml fell from 82.4% in March to 71.9% in mid-July.
Pharmaceutical Technology
AUGUST 11, 2022
US-based company Johnson & Johnson’s IT hiring rose 11.0% in July 2022 when compared with the previous month, according to GlobalData’s Job Analytics database. The company’s overall hiring activity increased by 14.48% in July 2022 when compared with June 2022. IT jobs claimed a 4.2% share in the company’s total hiring activity in July 2022, and recorded a 0.21% growth over the last three-month average share.
PharmaVoice
AUGUST 11, 2022
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
Expert insights. Personalized for you.
149 
Let's personalize your content